>> My name is Brian Neman [assumed spelling].
I graduated from USC Bachelor's Biological Sciences in 2008 and Masters
in Health Care Policy and Management in 2010.
Immediately after I founded a biotechnology company Sanguine Biosciences
and I'm currently the CEO of the company and yeah everything has been going well.
It's three years now since I graduated.
So what the company does is we're creating a library of patient information including blood,
medical records, DNA, and patient information and researchers will be able
to access this information via the web
so that they can design more effective drugs for specific patient types.
Actually I was sitting in a genetics course at USC
and just hearing our professor speak I realized that there was going to be a big change
in the way medicine was delivered or health care was practiced,
specifically in terms of the DNA sequencing.
So when I was in school here the Alumina DNA sequencing machine that was the big revolution
and so I wanted to be a part of that change and I realized that if you're going to digitize all
of this biological information because a lot of what we are learning in school was
about how biological information was now becoming digitized and I saw that trend
and we wanted to be a part of it.
So I understood how the machines were able to do it,
I understand how raw physical DNA could transform to digital DNA but the library
or the aggregation of this data I was confused as to how that was going to happen.
So I started Sanguine with the idea of aggregating all of that.
Since the science part is so critical we decided we'd get that out
of the way first, build infrastructure for that.
So we spent a lot of time developing that so we don't really focus on that part just yet.
So now our focus is on human resources legal, finance, setting up different departments,
patient engagement, patient advocacy, setting that part up, sales, business development,
commercialization, long term plans and storage such as new facility that we want to get,
new equipment, financing of that equipment.
I spend fifty percent of my day in interviews, the other fifty percent with the team,
and in the next couple of months it's going to change to fifty percent with sales people,
or fifty percent with the investors and the fifty percent with the management team.